Spruce Biosciences Inc. is a biopharmaceutical company. It focuses on developing and commercializing novel therapies for rare endocrine disorders. The company develops tildacerfont, an non-steroidal therapy which are in clinical stage. Spruce Biosciences Inc. is based in Daly City, California.
| Revenue (Most Recent Fiscal Year) | $4.91M |
| Net Income (Most Recent Fiscal Year) | $-53.04M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 1.03 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.38 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -3721.17% |
| Net Margin (Trailing 12 Months) | -1079.94% |
| Return on Equity (Trailing 12 Months) | -177.45% |
| Return on Assets (Trailing 12 Months) | -118.06% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.60 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.60 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $52.47 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-3.50 |
| Earnings per Share (Most Recent Fiscal Year) | $-96.99 |
| Diluted Earnings per Share (Trailing 12 Months) | $-86.21 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 0.56M |
| Free Float | 0.52M |
| Market Capitalization | $5.06M |
| Average Volume (Last 20 Days) | 2942.40 |
| Beta (Past 60 Months) | 2.43 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 6.90% |
| Percentage Held By Institutions (Latest 13F Reports) | 91.71% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |